Core Insights - The 11th Bio-based Conference and Exhibition will be held in Shanghai from May 20-22, focusing on bio-based chemicals and materials, featuring 11 thematic forums, 7 concurrent activities, and 1000 new product displays [2] Group 1: Company Overview - Kasei Biotech, established in 2000, focuses on synthetic biology and bio-manufacturing technology, becoming a global leader in producing new bio-based materials [3] - Kasei Biotech's revenue for 2025 is projected to reach 3.295 billion yuan, marking an 11.41% increase, with a net profit of 566 million yuan, up 15.7% [3] - Huaheng Biotech, founded in 2005, plans to list in Hong Kong and expects a revenue of 2.885 billion yuan in 2025, a 32.5% increase, but a net profit decrease of approximately 30% [9][10] - Huadong Medicine achieved a revenue of 41.906 billion yuan in 2024, a 3.16% increase, with a net profit of 3.512 billion yuan, up 23.72% [14] Group 2: Main Business Composition - Kasei Biotech's main revenue sources include long-chain dicarboxylic acids (2.67 billion yuan, 90.26% of revenue) and bio-based polyamides (144 million yuan, 4.88% of revenue) [6] - Huaheng Biotech's main products include amino acids (1.509 billion yuan, 69.29% of revenue) and vitamins (207 million yuan, 9.49% of revenue) [10] - Huadong Medicine's industrial microbiology segment saw revenue growth from 510 million yuan in 2022 to 711 million yuan in 2024, with a CAGR of 18.07% [14] Group 3: Research and Development Projects - Kasei Biotech is investing in projects like bio-manufacturing research with a total investment of 6.3 million yuan, focusing on fermentation and extraction technology [7] - Huaheng Biotech has multiple ongoing projects, including optimizing amino acid production strains and developing high-purity amino acid removal processes [11][12] - Huadong Medicine has initiated 393 research projects in industrial microbiology, focusing on xRNA raw materials and health-related products [18] Group 4: Development Strategies - Kasei Biotech aims to expand large-scale applications of bio-materials to replace petrochemical products and utilize agricultural waste for bio-manufacturing [8] - Huaheng Biotech focuses on becoming a leader in synthetic biology through innovation and collaboration, emphasizing the use of renewable resources [13] - Huadong Medicine is accelerating its business layout through cooperation and acquisitions, focusing on xRNA raw materials and health products [25] Group 5: Financial Performance - Kasei Biotech's revenue for 2025 is projected to be 3.295 billion yuan, with a net profit of 566 million yuan [3] - Huaheng Biotech expects a revenue of 2.885 billion yuan in 2025, with a significant decrease in net profit [9] - Huadong Medicine's revenue reached 41.906 billion yuan in 2024, with a notable increase in net profit [14] Group 6: Market Trends - The bio-based industry is witnessing a shift towards sustainable materials, with companies focusing on reducing reliance on fossil fuels and enhancing the use of agricultural by-products [8][13] - The demand for bio-based products is expected to grow, driven by environmental concerns and regulatory support for sustainable practices [2][8]

Core Viewpoint - The chairman of Huaxi Biological, Zhao Yan, expressed that the company does not regret its previous rebuttal of the "hyaluronic acid is outdated" theory, aiming to bring the industry back to a rational era [1][2]. Group 1: Industry Insights - Zhao Yan emphasized that the emergence of new substances should not lead to the denigration of existing ones, highlighting that both collagen and hyaluronic acid have synergistic effects in the market [1][2]. - The focus should return to scientific principles in product development, with companies prioritizing research and development and establishing their foundational logic rather than engaging in blind competition [1][2]. Group 2: Dialogue Highlights - The dialogue, part of the "Qian Dao" series produced by Sina Finance and Weibo, featured Zhao Yan discussing organizational aging, cognitive alignment, and rebuilding execution logic with Song Lixin, chairman of Yicai Yuan Investment Management [1][2].

Group 1 - Xinjiang Jinyu Textile Co., Ltd. is operating its spinning production line efficiently, with workers accelerating the production of order products [2] - The agricultural sector is actively preparing for spring farming, with a focus on improving crop yields and quality through training and technical support [5][7] - The company Xinjiang Yilihong Biological New Materials Technology Co., Ltd. has achieved an automation control rate of over 80% in its production processes, leading to a continuous industrial output growth rate exceeding 40% for two consecutive years [8] Group 2 - Xinjiang Fengda Cotton Industry Technology Co., Ltd. has signed over 1 million meters of fabric orders, achieving full production capacity with a daily output of 30,000 meters of fabric [8] - The logistics sector is enhancing efficiency through innovative models, such as the "front warehouse" approach, significantly shortening procurement distances for downstream enterprises [10] - The China Post Group's Aral City branch has resumed full operations, with approximately 4,000 packages being delivered on the first day back to work after the holiday [11] Group 3 - The Six Division Wujiaqu City Government Service Hall has improved service efficiency by increasing service windows and optimizing business processing, now handling 668 government service items [12] - The agricultural technology advancements in strawberry cultivation have led to over 300 farmers increasing their income, with the related industry achieving a comprehensive output value exceeding 40 million yuan [3] - The automotive market in Xinjiang is expanding, with the Xinjiang Tianhengji International Automotive Culture City serving as a significant hub for domestic and international vehicle transactions, achieving an annual transaction volume exceeding 10 billion yuan [10]

Group 1: Medical Aesthetics Industry - The Chinese medical aesthetics market is expected to reach nearly 370 billion by 2025, with a high growth outlook for the recombinant collagen segment [2][35] - The trend of younger consumers in medical aesthetics is evident, with light medical aesthetics gradually becoming mainstream, accounting for 52% of the market in 2022 [7][12] - Approximately 50.90% of users choose medical aesthetics because "becoming beautiful can make oneself happier," indicating a strong emotional value associated with beauty [4][8] Group 2: Beauty Industry - The retail sales of cosmetics in China are projected to grow at a CAGR of about 9% from 2016 to 2024, with domestic brands expected to maintain growth momentum [2][3] - The Chinese cosmetics market is entering a phase of high-quality development, with trends leaning towards scientific beauty and Eastern philosophies [3][19] - The market for cosmetic raw materials is expected to grow from 1147.80 billion in 2019 to 1603.90 billion by 2024, with a CAGR of 6.9% [2][3] Group 3: Related Companies on the Beijing Stock Exchange - Companies such as Jinbo Biological, which leads in recombinant human collagen medical devices, and Bawei Co., which provides ODM services for domestic and international cosmetic brands, are expected to benefit from the ongoing beauty consumption boom [2][3] - The market for functional skincare products is also seeing new entrants, with companies like Jinbo Biological expanding into this segment [2][3] - The beauty industry is experiencing a transformation driven by technological innovations, including synthetic biology and the application of new materials [2][3]

Core Viewpoint - China Resources Biopharma (华润医药) announced a significant decline in the net profit of its subsidiary, China Resources Boya Biopharma (华润博雅生物), for the fiscal year ending December 31, 2025, primarily due to market challenges and the impact of acquisitions [1][2] Group 1: Financial Performance - The net profit attributable to shareholders of China Resources Boya Biopharma is expected to be approximately RMB 105 million to RMB 136.5 million, a substantial decrease from RMB 397 million in the previous year [1] - The expected net loss, after excluding non-recurring items, is projected to be between RMB 7.5 million and RMB 15 million, compared to a net profit of RMB 302 million in the prior year [1] - The anticipated impact of non-recurring items on net profit is about RMB 120 million, influenced by government subsidies, asset sales, and wealth management income [2] Group 2: Business Challenges - The decline in net profit is largely attributed to a downturn in the market for hyaluronic acid products distributed by Anhui Greenke Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Green Cross Hong Kong Holdings, which was acquired in November 2024 [2] - The acquisition of Green Cross Hong Kong Holdings has led to impairment losses on intangible assets and goodwill totaling approximately RMB 300 million [2] - The blood products business of China Resources Boya Biopharma has faced challenges due to expanded centralized procurement, DRG/DIP reforms, medical insurance cost controls, and increased regulatory scrutiny, resulting in reduced clinical prescriptions and demand [2] Group 3: Strategic Initiatives - China Resources Boya Biopharma is committed to implementing the "1246" model and is focusing on "four remolds" (value remolding, business remolding, organizational remolding, and spiritual remolding) to navigate the complex market environment [1] - The company anticipates a year-on-year increase in operating revenue of 10% to 25%, primarily driven by the acquisition of Green Cross Hong Kong Holdings [1]

Core Viewpoint - China Resources Pharmaceutical (华润医药) announced a significant decline in the net profit of its subsidiary, China Resources Boya Bio (华润博雅生物), for the fiscal year ending December 31, 2025, primarily due to market challenges and the impact of acquisitions [1][2] Group 1: Financial Performance - The net profit attributable to shareholders of China Resources Boya Bio is expected to be approximately RMB 105 million to RMB 136.5 million, a substantial decrease from the previous year's net profit of approximately RMB 397 million [1] - The expected net loss attributable to shareholders, after excluding non-recurring gains and losses, is projected to be between RMB 7.5 million and RMB 15 million, compared to a net profit of approximately RMB 302 million in the previous year [1] - The anticipated impact of non-recurring gains and losses on net profit is about RMB 120 million, influenced by government subsidies, asset sales, and wealth management income [2] Group 2: Business Challenges - The decline in net profit is largely attributed to the underperformance of aesthetic medical products, specifically hyaluronic acid, distributed by Anhui Greenke Pharmaceutical Co., which is a wholly-owned subsidiary of Green Cross Hong Kong Holdings, acquired by China Resources Boya Bio in November 2024 [2] - The company faced significant impairment losses on intangible assets and goodwill totaling approximately RMB 300 million due to the market downturn [2] - The blood products business of China Resources Boya Bio has been adversely affected by intensified market competition, expanded centralized procurement, and reforms in medical insurance, leading to a decrease in clinical prescriptions and demand, as well as a decline in gross margin year-on-year [2] Group 3: Strategic Initiatives - During the reporting period, China Resources Boya Bio is committed to implementing the "1246" model and focusing on "four remolds" (value remolding, business remolding, organizational remolding, and spiritual remolding) to navigate the complex market environment and drive academic development [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於香港註冊成立的有限公司） （股份代號：3320） 公告 華潤博雅生物截至2025年12月31日止年度的 業績預告 於 2026 年 1 月 30 日， 華 潤 博雅 生 物 公 佈其 截 至 2025 年 12 月31 日 止年 度 的 業績 預 告。 華潤博雅生物製藥集團股份有限公司（「華潤博雅生物」）為一家於中華人民共和國 註 冊 成 立 的 公 司 。 華 潤 博 雅 生 物 的 股 份 於 深 圳 證 券 交 易 所 上 市 。 截 至 本 公 告 日 期，華潤醫藥集團有限公司（「本公司」，連同其附屬公司合稱為「本集團」）間接持 有華潤博雅生物總股本約30.48 %及總股本約41.79 %表決權，因此華潤博雅生物為 本公司的附屬公司。 於 2026 年 1 月 30 日 ， 華 潤 博 雅 生 物 公 佈 其 截 至 2025 ...

Group 1 - The "Top Ten Outstanding Figures in the Medical Aesthetics Industry for 2025" list was announced by Rui Finance, highlighting Zhao Yan, the Chairman of Huaxi Biological, as a notable figure [1] - The selection criteria for the list included professional ability, performance, and industry influence [1] - Zhao Yan has been instrumental in the strategic transformation, R&D investment, and technological innovation of the group, solidifying its leading position in hyaluronic acid globally and expanding into cutting-edge fields like synthetic biology and regenerative medicine [2] Group 2 - Zhao Yan was born in July 1966 and holds a bachelor's degree in biology and an MBA from Fordham University [2] - She served as the General Manager of Huaxi Xinyu Investment Co., Ltd. from 2000 to 2002 and was a board member of Huaxi Furuida Biopharmaceutical Co., Ltd. from 2003 until March 2019 [2] - Currently, she holds the positions of Chairman and General Manager of the company [2]

Core Viewpoint - Huaxi Bio, a leading company in the biomanufacturing sector, emphasizes the importance of innovation and collaboration among research institutions, enterprises, and government to drive the development of the biomanufacturing industry and achieve market transformation [3][8]. Industry Insights - The competition in the hyaluronic acid market is intensifying, with a focus on technological accumulation and long-term development paths among leading companies [3]. - The industry is shifting from a focus on single products to systemic solutions, highlighting the need for creativity and responsible marketing practices [6]. - The current market is characterized by a lack of innovation, with many companies resorting to imitation rather than developing unique solutions [6]. Talent Development - The biomanufacturing sector requires talent with interdisciplinary knowledge, including biology, engineering, AI, and bioinformatics, to meet the demands of future industry growth [7]. - Attracting creative and self-driven talent in synthetic biology is essential, necessitating a collaborative effort from government, enterprises, and individuals [7]. Policy and Government Role - Beijing has implemented policies to accelerate the innovation and market transformation of the synthetic biology manufacturing industry, demonstrating a strong governmental commitment [8]. - Local initiatives, such as those in Changping District, aim to attract relevant enterprises and talent, creating a multi-layered support system for the industry [8]. Market Transformation Challenges - The main challenge for innovative companies is the effective market transformation of new products, often hindered by strict intellectual property protection and insufficient collaboration mechanisms with research institutions [9]. - A call for government intervention to establish rules and standards for better cooperation between researchers and enterprises is emphasized, aiming to increase the current low conversion rate of research outcomes [9]. AI's Impact on Biomanufacturing - AI is becoming a foundational capability in the biomanufacturing and biotechnology sectors, with companies needing to embrace AI to survive and thrive [10]. - The integration of AI is expected to reshape business logic and organizational structures, potentially leading to exponential growth in the industry [11]. - AI has the potential to bridge the gap between China and developed countries in the biotechnology field, facilitating innovation and enhancing data-driven decision-making [11].

Core Viewpoint - The survival of future enterprises hinges on their ability to truly embrace AI, which is seen as a transformative force in the industry [2][12]. Group 1: Company Overview - Huaxi Biological is a prominent player in the biomanufacturing sector, spanning various fields including active substances, pharmaceuticals, medical aesthetics, functional skincare, and food [2]. - The company has been in the spotlight over the past year, particularly during the Fourth Session of the 14th Beijing Municipal Committee of the Chinese People's Political Consultative Conference [2]. Group 2: Industry Insights - The market for hyaluronic acid and other regenerative materials is becoming increasingly competitive, with a focus on innovation rather than mere imitation [3][5]. - The industry is shifting from single-product offerings to systemic solutions that address consumer needs, emphasizing the importance of scientific backing and social responsibility [5]. Group 3: Talent and Innovation - The transition from manufacturing to creation in biotechnology requires talent with interdisciplinary knowledge, including biology, engineering, AI, and bioinformatics [6][8]. - Attracting creative and self-driven talent in synthetic biology is a collaborative effort involving government, enterprises, and the talent pool itself [8]. Group 4: Policy and Market Transformation - Beijing has implemented policies to accelerate the innovation and market transformation of synthetic biology, demonstrating a strong governmental commitment to this sector [8][9]. - The current bottleneck in innovation lies in the tight control of early-stage intellectual property by academic researchers, which hinders collaboration with enterprises [9]. Group 5: AI's Impact on the Industry - AI is becoming a foundational capability in biomanufacturing, with companies needing to adapt their business logic and organizational structures to survive [10][12]. - The advent of AI is seen as a means to level the playing field in biotechnology, potentially leading to exponential growth through redefined innovation logic [12].